NASDAQ:CAPR

Capricor Therapeutics - CAPR Stock Forecast, Price & News

$5.86

-0.10 (-1.68%)

(As of 09/29/2022 01:20 PM ET)

Add

Compare

Today's Range: $5.86
▼
$6.10
50-Day Range: $4.37
▼
$6.08
52-Week Range: $2.56
▼
$6.21

Volume: 1,216 shs
Average Volume: 193,795 shs
Market Capitalization: $142.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

Capricor Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 203.5% Upside
$18.00 Price Target
Short Interest: Healthy
0.88% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.47
Based on 5 Articles This Week
Insider Trading: Selling Shares
$106,371 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.17) to ($1.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

244th out of 1,096 stocks

Pharmaceutical Preparations Industry

107th out of 548 stocks

3.5

Analyst's Opinion

Consensus Rating
Capricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.00, Capricor Therapeutics has a forecasted upside of 203.5% from its current price of $5.93.
Amount of Analyst Coverage
Capricor Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.88% of the outstanding shares of Capricor Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Capricor Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Capricor Therapeutics has recently decreased by 25.52%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Capricor Therapeutics does not currently pay a dividend.
Dividend Growth
Capricor Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CAPR.

3.6

News and Social Media Coverage

News Sentiment
Capricor Therapeutics has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Capricor Therapeutics this week, compared to 1 article on an average week.
Search Interest
7 people have searched for CAPR on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Capricor Therapeutics insiders have sold 1,041.32% more of their company's stock than they have bought. Specifically, they have bought $9,320.00 in company stock and sold $106,371.00 in company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Capricor Therapeutics is held by insiders.
Percentage Held by Institutions
Only 10.43% of the stock of Capricor Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.17) to ($1.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Capricor Therapeutics is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Capricor Therapeutics is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Capricor Therapeutics has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPR Stock News Headlines

September 9, 2022 | finance.yahoo.com

Capricor Therapeutics, Inc. (CAPR)

September 7, 2022 | finance.yahoo.com

Capricor Therapeutics to Present at Upcoming Investor Conferences

August 10, 2022 | seekingalpha.com

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2022 Results Earnings Call Transcript

August 10, 2022 | finance.yahoo.com

Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 3, 2022 | finance.yahoo.com

Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10

July 19, 2022 | latimes.com

Finalist: Anthony J. Bergmann

July 19, 2022 | msn.com

Capricor Initiates Late-Stage Neuropsychiatric Disorder Study

July 19, 2022 | finance.yahoo.com

Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

July 10, 2022 | markets.businessinsider.com

More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying

June 27, 2022 | seekingalpha.com

Capricor posts statistically significant data for DMD candidate in open-label trial

June 27, 2022 | finance.yahoo.com

Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study

May 25, 2022 | finance.yahoo.com

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

May 18, 2022 | finance.yahoo.com

Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022 | finance.yahoo.com

Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 10, 2022 | seekingalpha.com

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q1 2022 Results - Earnings Call Transcript

May 10, 2022 | finance.yahoo.com

Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 3, 2022 | finance.yahoo.com

Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10

May 2, 2022 | finance.yahoo.com

Loss-Making Capricor Therapeutics, Inc. (NASDAQ:CAPR) Expected To Breakeven In The Medium-Term

March 29, 2022 | finance.yahoo.com

Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit

March 28, 2022 | finance.yahoo.com

Cara Therapeutics' Difelikefalin Improves Itch, Inflammatory Biomarkers In Skin Disorders

March 28, 2022 | nasdaq.com

Capricor: Phase 2 INSPIRE Study With CAP-1002 Meets Primary Objective Of Safety

March 28, 2022 | finance.yahoo.com

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

March 28, 2022 | marketwatch.com

Capricor Therapeutics Shares Tumble on Covid-19 Study Update >CAPR

March 28, 2022 | seekingalpha.com

Capricor Therapeutics COVID treatment meets safety objective in mid-stage trial

March 28, 2022 | finance.yahoo.com

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPR Company Calendar

Last Earnings: 8/10/2022
Today: 9/29/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CAPR
CUSIP: N/A
CIK: 1133869
Web: www.capricor.com
Phone: 310-358-3200
Fax: 415-875-7075
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.00
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +207.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,020,000.00
Net Margins: N/A
Pretax Margin: -11,122.06%
Return on Equity: -89.89%
Return on Assets: -48.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.69
Quick Ratio: 2.69

Sales & Book Value

Annual Sales: $250,000.00
Price / Sales: 570.76
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.30 per share
Price / Book: 4.51

Miscellaneous

Outstanding Shares: 24,350,000
Free Float: 22,155,000
Market Cap: $142.69 million
Optionable: Not Optionable
Beta: 4.84

Key Executives

Frank I. Litvack M.D. (Age 59)
Independent Executive Chairman of the Board

Linda Marban Ph.D. (Age 51)
President, Chief Executive Officer, Director

Anthony Bergmann (Age 32)
Chief Financial Officer, Principal Accounting Officer

Karen G. Krasney J.D. (Age 62)
Executive Vice President, General Counsel

Thomas Lyle Copmann Ph.D. (Age 61)
Vice President - Regulatory Affairs and Drug Development

Houman Hemmati M.D.
Ph.D., Vice President - Medical & Clinical Development, New Therapies

Luis Rodriguez-Borlado Ph.D.
Vice President - Regenerative Therapies

Rachel Smith Ph.D. (Age 36)
Vice President - Research & Development

Deborah Ascheim M.D.
Chief Medical Officer

Joshua A. Kazam (Age 40)
Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CAPR Stock - Frequently Asked Questions

Should I buy or sell Capricor Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CAPR shares.
View CAPR analyst ratings or view top-rated stocks.
What is Capricor Therapeutics' stock price forecast for 2022?: 1 analysts have issued 1 year price objectives for Capricor Therapeutics' stock. Their CAPR share price forecasts range from $18.00 to $18.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 202.0% from the stock's current price.
View analysts price targets for CAPR or view top-rated stocks among Wall Street analysts.
How have CAPR shares performed in 2022?: Capricor Therapeutics' stock was trading at $2.93 at the beginning of the year. Since then, CAPR stock has increased by 103.4% and is now trading at $5.96.
View the best growth stocks for 2022 here.
When is Capricor Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CAPR earnings forecast.

How were Capricor Therapeutics' earnings last quarter?: Capricor Therapeutics Inc (NASDAQ:CAPR) issued its earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.04. During the same quarter in the prior year, the firm earned ($0.21) earnings per share.
What other stocks do shareholders of Capricor Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).
What is Capricor Therapeutics' stock symbol?: Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How do I buy shares of Capricor Therapeutics?: Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Capricor Therapeutics' stock price today?: One share of CAPR stock can currently be purchased for approximately $5.96.
How much money does Capricor Therapeutics make?: Capricor Therapeutics (NASDAQ:CAPR) has a market capitalization of $145.13 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-20,020,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.
How can I contact Capricor Therapeutics?: Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The official website for the company is www.capricor.com. The biotechnology company can be reached via phone at 310-358-3200, via email at kimberly@argotpartners.com, or via fax at 415-875-7075.

This page (NASDAQ:CAPR) was last updated on 9/29/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Capricor Therapeutics - CAPR Stock Forecast, Price & News

Capricor Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Capricor Therapeutics (NASDAQ:CAPR) Stock

CAPR Stock News Headlines

CAPR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CAPR Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™